ISSN: 0973-7510

E-ISSN: 2581-690X

Mini Review | Open Access
Rehan Deshmukh1 and Utpal Roy2
1School of Biosciences and Technology, Faculty of Science, Dr. Vishwanath Karad MIT-World Peace University, Paud Road, Pune, Maharashtra, India.
2Department of Biological Sciences, Birla Institute of Technology and Science Pilani, KK Birla Goa Campus, NH17B Bypass, Goa, India.
Article Number: 8191 | © The Author(s). 2023
J Pure Appl Microbiol. 2023;17(1):1-11.
Received: 25 October 2022 | Accepted: 12 December 2022 | Published online: 24 January 2023
Issue online: March 2023

The world has been rocked by the 2019 coronavirus disease (COVID-19), which has significantly changed our way of life. Despite the unusual measures taken, COVID-19 still exists and affects people all over the world. A remarkable amount of study has been done to find ways to combat the infection’s unsurpassed level. No ground-breaking antiviral agent has yet been introduced to remove COVID-19 and bring about a return to normalcy, even though numerous pharmaceuticals and therapeutic technologies have been reused and discovered. The cytokine storm phenomenon is of utmost importance since fatality is strongly connected with the severity of the disease. This severe inflammatory phenomenon marked by increased amounts of inflammatory mediators can be targeted for saving patients’ life. Our analysis demonstrates that SARS-CoV-2 specifically generates a lot of interleukin-6 (IL-6) and results in lymphocyte exhaustion. Tocilizumab is an IL-6 inhibitor that is currently thought to be both generally safe and effective. Additionally, corticosteroids, tumor necrosis factor (TNF)-blockers and Janus kinase (JAK) inhibitors could be effective and dependable methods to reduce cytokine-mediated storm in SARS-CoV-2 patients.


SARS-CoV-2, Cytokine Storm, Nucleoside Analogues, JAK Inhibitors, Diabetes

Article Metrics

Article View: 55

Share This Article

© The Author(s) 2023. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.